Retroviral coinfections: HIV and HTLV: Taking stock of more than a quarter century of research

AIDS Research and Human Retroviruses

Volumn 28, Issue 2, 2012, Pages 139-147

  Beilke, Mark A ^a  

^a CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TAX PROTEIN;

CD4+ T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; HUMAN T CELL LEUKEMIA VIRUS INFECTION; HUMAN T LYMPHOTROPIC VIRUS 3; IMMUNOPATHOLOGY; LEUKEMIA; LYMPHOMA; MIXED INFECTION; NEUROLOGICAL COMPLICATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SEROEPIDEMIOLOGY; VIRUS DETECTION; VIRUS GENOME; VIRUS ISOLATION; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION; WESTERN BLOTTING;

AFRICA; AMERICAS; BIOMEDICAL RESEARCH; CD4 LYMPHOCYTE COUNT; COINFECTION; EUROPE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HIV INFECTIONS; HIV-1; HTLV-I INFECTIONS; HTLV-II INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 2; HUMANS; LYMPHOMA, AIDS-RELATED; PREVALENCE; SEROEPIDEMIOLOGIC STUDIES; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84858026627     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0342     Document Type: Review

References (96)

1. van der Kuyl AC and Cornelissen M: Identifying HIV-1 dual infections. Retrovirology 2007;4(67):1-12.
2. McCutchan FE, Hoelscher M, Tovanabutra S, Piyasirisilp S, Sanders-Buell E, Ramos G, Jagodzinski L, Polonis V, Maboko L, Mmbando D, Hoffmann O, Riedner G, von Sonnenburg F, Robb M, and Birx DL: In-depth analysis of a heterosexually acquired human immunodeficiency virus type 1 superinfection: Evolution, temporal fluctuation, and intercompartment dynamics from the seronegative window period through 30 months postinfection. J Virol 2005;79(18):11693-11704. (Pubitemid 41279288)
3. Taylor JE and Korber BT: HIV-1 intra-subtype superinfection rates: Estimates using a structured coalescent with recombination. Infect Genet Evol 2005;5(1):85-95. (Pubitemid 39619021)
4. Chakraborty B, Valer L, De Mendoza, C. Soriano V, and Quinones-Mateu ME: Failure to detect human immunodeficiency virus type 1 superinfection in 28 HIV-seroconcordant individuals with high risk of reexposure to the virus. AIDS Res Hum Retroviruses 2004;20(9):1026-1031. (Pubitemid 39369711)
5. Fang G, Weiser B, Kuiken C, Philpott SM, Rowland-Jones S, Plummer F, Kimani J, Shi B, Kaul R, Bwayo J, Anzala O, and Burger H: Recombination following superinfection by HIV-1. AIDS 2004;18(2):153-159. (Pubitemid 38253436)
6. Hu DJ, Subbarao S, Vanichseni S, Mock PA, Ramos Artur, Nguyen L, Chaowanachan T, Griensven F, Choopanya K, Mastro TD, and Tappero JW: Frequency of HIV-1 dual subtype infections, including intersubtype superinfections, among injection drug users in Bangkok, Thailand. AIDS 2005;19(3):303-308. (Pubitemid 40396562)
7. Fultz PN: HIV-1 superinfections: Omens for vaccine efficacy? AIDS 2004;18(1):115-119.
8. Shine D, Moll B, Emeson E, Spigland I, Harris C, Small CB, Friedland G, Weiss SH, and Bodner AJ: Serologic, immunologic, and clinical features of parenteral drug users from contrasting populations. Am J Drug Alcohol Abuse 1987;13(4):401-412.
9. Pierik LT and Murphy EL: The clinical significance of HTLVI and HTLV-II infection in the AIDS epidemic. AIDS Clin Rev 1991;1:39-57.
10. Khabbaz RF, Onorato IM, Cannon RO, Hartley TM, Roberts B, Hosein B, and Kaplan JE: Seroprevalence of HTLV-I and HTLV-II among intravenous drug users and persons in clinics for sexually transmitted diseases. N Engl J Med 1992;326(6):375-380.
11. Wiktor SZ, Cannon RO, Atkinson WL, Lutz B, Hook EW, Blattner WA, and Quinn TC: Infection with HTLV-II and -II in sexually transmitted disease clinics in Baltimore and New Orleans. J Infect Dis 1992;165(5):920-924.
12. Briggs NC, Battjes RJ, Cantor KP, Blattner WA, Yellin FM, Wilson S, Ritz AL, Weiss SH, and Goedert JJ: Seroprevalence of HTLV-II infection, with or without HIV-1 coinfection, among US intravenous drug users. J Infect Dis 1995;172(1):51-58.
13. Bessinger R, Beilke M, Kissinger P, Jarrott C, and Tabak OF: Retroviral coinfections at a New Orleans HIV outpatient clinic. J AIDS Human Retrovirol 1997;14(1):67-71.
14. Kaplan JE and Khabbaz RF: The epidemiology of human T-lymphotropic virus types I and II. Rev Med Virol 1993;3:137.
15. Dezzutti CS and Lal RB: Human T-cell lymphotropic virus types I and II. In: Manual of Clinical Microbiology (Murray PR, Baron KJ, Pfaller MA, et al., eds.). American Society for Microbiology, Washington, DC, 1999, p. 871.
16. Araujo A, Sheehy N, Takahashi H, and Hall WW: Concomitant infections with human immunodeficiency virus type 1 and human T-lymphotropic virus types 1 and 2. In: Polymicrobial Diseases (Brogden KA and Guthmiller JM, eds.). ASM Press, Washington, DC, 2002, Chapter 5.
17. Schreiber GB, Murphy EL, Horton JA, Wright DJ, Garfein R, Chien HC, and Nass CC: Risk factors for human T-cell lymphotropic virus types I and II (HTLV-I and -II) in blood donors: The retrovirus epidemiology donor study. NHLBI retrovirus epidemiology donor study. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14(3):263-271.
18. Barcellos NT, Fuchs SC, Mondini LG, and Murphy EL: Human T lymphotropic virus type I/II infection: Prevalence and risk factors in individuals testing for HIV in counseling centers from Southern Brazil. Sex Trans Dis 2006;33(5):302-306. (Pubitemid 43964599)
19. Murphy EL, Watanabe K, Nass CC, Ownby H, Williams A, and Nemo G: Evidence among blood donors for a 30-year old epidemic of human T lymphotropic virus type II infection in the United States. J Infect Dis 1999;180(6):1777-1783.
20. Zella D, Mori L, Sala M, Ferrante P, Casoli C, Magnani G, Achilli G, Cattaneo E, Lori F, and Bertazzoni U: HTLV-II infection in Italian drug abusers. Lancet 1990;336(8714):575-576. (Pubitemid 20278149)
21. Fukushima Y, Takahashi H, Hall WW, Nakasone T, Nakata S, Song P, Duc DD, Hien B, Quang NX, Trinh TN, Nishioka K, Kitamura K, Komuro K, Vahlne A, and Honda M: Extraordinary high rate of HTLV type II seropositivity in intravenous drug abusers in south Vietnam. AIDS Res Hum Retroviruses 1995;11(5):637-645.
22. Edlin BR, Irwin KL, Faruque S, McCoy CB, Word C, Serrano Y, Inciardi JA, Bowser BP, Schilling RF, Holmberg SD, and the Multicenter Crack Cocaine and HIV Infection Study Team. Intersecting epidemics - crack cocaine use and HIV infection among inner-city young adults. N Engl J Med 1994;331(21):1422-1427.
23. Substance Abuse and Mental Health Services Administration (SAMHSA) Report: National survey shows a rise in illicit drug use from 2008 to 2010. SAMHSA News Report September 8, 2011: http://www.samhsa.gov.
24. Poiesz BJ, Buscetti FW, Gazdar AF, Bunn PA, Minna JD, and Gallo RC: Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980;77(12):7415-7419. (Pubitemid 11131140)
25. Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, Kinoshita KI, Shirahawa S, and Miyoshi I: Adult T-cell leukemia: Antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA 1981;78(10):6476-6480. (Pubitemid 12179735)
26. Miyoshi I, Kubonishi I, Yoshimoto S, Akagi T, Ohtsuki Y, Shiraishi Y, Nagata K, and Hinuma Y: Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells. Nature 1981;294(5843):770-771. (Pubitemid 12174453)
27. Yoshida M, Seiki M, Yamaguchi K, and Takatsuki K: Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc Natl Acad Sci USA 1984;81(8):2534-2537.
28. Kalyanaraman VS, Sarngadharan MG, Robert-Guroff M, Miyoshi I, Golde D, and Gallo RC: A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science 1982;218(4572):571-573. (Pubitemid 12003042)
29. Gessain A, Barin F, Vernant JC, Gout O, Maurs L, Calender A, and de The G: Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985;2(8452):407-410. (Pubitemid 15231248)
30. Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A, Matsumoto M, and Tara M: HTLV-I associated myelopathy, a new entity. Lancet 1986;1(8488):1031- 1032. (Pubitemid 16102987)
31. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, Rozenbaum W, and Montagnier L: Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220(4599):868-871. (Pubitemid 13080157)
32. Broder S and Gallo RC: A pathogenic retrovirus (HTLV-III) linked to AIDS. N Engl J Med 1984;311(20):1992-1297.
33. Harada S, Koyangi Y, and Yamamoto N: Infection of HTLV-III/ LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science 1985;229(4713):563-566. (Pubitemid 16239336)
34. Coffin J, Haase A, Levy JA, Montagnier L, Oroszlan S, Teich N, Temin H, Toyoshima K, Varmus H, Vogt P, and Weiss R: Human immunodeficiency viruses [letter]. Science 1986;232(4751):697.
35. Coffin J, Haase A, Levy JA, Montagnier L, Oroszlan S, Teich N, Temin H, Toyoshima K, Varmus H, Vogt P, and Weiss R: What to call the AIDS virus? [letter]. Nature 1986;821(6065):10.
36. Gonda MA, Wong-Staal F, Gallo RC, Clements JE, Narayan O, and Gilden RV: Sequence homology and morphologic similarity of HTLV-III and Visna virus, a pathogenic lentivirus. Science 1985;227(4683):173-177. (Pubitemid 15154222)
37. Popovic M, Read-Connole E, and Gallo RC: T4 positive human neoplastic cell lines susceptible to and permissive for HTLV-III. Lancet 1984;2(8417-8418):1472-1473. (Pubitemid 15175156)
38. Koenig S, Gendelman HE, Orenstein JM, Dal Canto MC, Pezeshkpour GH, Yungbluth M, Janott F, Aksamit A, Martin MA, and Fauci AS: Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 1986;233(4768):1089-1093. (Pubitemid 16032241)
39. Seiki M, Hattori S, Hirayama Y, and Yoshida M: Human adult T-cell leukemia virus: Complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA. Proc Natl Acad Sci USA 1983;80(12):3618-3622. (Pubitemid 13063122)
40. Shimotohno K, Takahashi Y, Shimizu N, Gojobori T, Golde DW, Chen ISY, Miwa M, and Sugimura T: Complete nucleotide sequence of an infectious clone of human T-cell leukemia virus type II: An open reading frame for the protease gene. Proc Natl Acad Sci USA 1985;82(10):3101-3105. (Pubitemid 15029553)
41. Ratner L, Haseltine W, Patarca R, Livak KJ, Starcich B, Josephs SF, Doran E, Rafalski JA, Whitehorn EA, Baumeister K, et al.: Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 1985;313(6000):277-284. (Pubitemid 15151982)
42. Schüpbach J, Gilden R, Gonda MA, Sarngadharan MG, and Gallo RC: Serological analysis of a subgroup of human T-lymphotropic retroviruses (HTLV-III) associated with AIDS. Science 1984;224(4648):503-505. (Pubitemid 14134742)
43. Essex M, McLane MF, Lee TH, Tachibana N, Mullins JI, Kreiss J, Kasper CK, Poon M-C, Landay A, Stein SF, Francis DP, Cabradilla C, Lawrence DN, and Evatt BL: Antibodies to human T-cell leukemia virus membrane antigens (HTLV-MA) in hemophiliacs. Science 1983;221(4615):1061-1064. (Pubitemid 13041958)
44. Sarngadharan MG, Bruch L, Popovic M, and Gallo RC: Immunological properties of the Gag protein p24 of the acquired immunodeficiency syndrome retrovirus (human T-cell leukemia virus type III). Proc Natl Acad Sci USA 1985;82(10):3481-3484. (Pubitemid 15030708)
45. Casey JM, Kim Y, Andersen PR, Watson KF, Fox JL, and Devare SG: Human T-cell lymphotropic virus type III: Immunologic characterization and primary structure analysis of the major internal protein, p24. J Virol 1985;55(2):417-423. (Pubitemid 16239730)
46. Abe T, Kinoshita T, Matsuda J, Ryu T, Ting RC, Aoki T, Robert-Guroff M, Miyakoshi H, and Gallo RC: Detection of antibodies to HTLV-I and -III in sera from Japanese hemophiliacs. Cancer Res 1985;45(9 Suppl):4621s-4623s. (Pubitemid 16223310)
47. Robert-Guroff M, Blayney DW, Safai B, Lange M, Gelmann M, Gutteman EP, Mansell JW, Goedtert PW, Groopman JL, Steigbigel JE, et al.: HTLV-1-specific antibody in AIDS patients and others at risk. Lancet 1984;2(8395):128-131.
48. Robert-Guroff M, Weiss SH, Giron JA, Jennings AM, Ginzburg HM, Margolis IB, Blattner WA, and Gallo RC: Prevalence of antibodies to HTLV-I, -II, and -III in intravenous drug abusers from an AIDS endemic region. JAMA 1986;255(22):3133-3137. (Pubitemid 16079597)
49. Bartholomew C, Blattner W, and Cleghorn F: Progression to AIDS in homosexual men co-infected with HIV and HTLV-I in Trinidad. Lancet 1987;2(8573):1469. (Pubitemid 18010356)
50. Hattori T, Koito A, Takatsuki K, Ikematsu S, Matsuda J, Mori H, Fukui M, Akashi K, and Matsumoto, K: Frequent infection with human T-cell lymphotropic virus type I in patients with AIDS but not in carriers of human immunodeficiency virus type 1. J Acquir Immune Defic Syndr Hum Retrovirol 1989;2(3);272-276. (Pubitemid 19147902)
51. Harper ME, Kaplan MH, Marselle LM, Pahwa SG, Chayt KJ, Sarngadharan MG, Wong-Staal F, and Gallo RC: Concomitant infection with HTLV-I and HTLV-III in a patient with T8 lymphoproliferative disease. N Eng J Med 1986;315(17):1073-1078. (Pubitemid 17170625)
52. Shibata D, Brynes RK, Rabinowitz A, Hanson CA, Slovak M, Spira TJ, and Gill P: Human T-cell lymphotropic virus type I (HTLV-I)-associated adult T-cell leukemia-lymphoma in a patient infected with human immunodeficiency virus type 1 (HIV-1). Ann Intern Med 1989;111(11):871-875. (Pubitemid 20000020)
53. Page JB, Lai S, Chitwood DD, Klimas NG, Smith PC, and Fletcher MA: HTLV-I/II positivity and death from AIDS among HIV-1 seropositive intravenous drug users. Lancet 1990;335(8703):1439-1441. (Pubitemid 20186444)
54. Heneine W, Khabbaz RF, Lal RB, and Kaplan JE: Sensitive and specific polymerase chain reaction assays for diagnosis of human T-cell lymphotropic virus type I (HTLV-I) and HTLV-III infections in HTLV-I/II-seropositive individuals. J Clin Micro 1992;30(6):1605-1607.
55. Ehrlich GD, Glaser JB, LaVigne K, Quan D, Mildvan D, Sninsky JJ, Kwok S, Papsidero L, and Poiesz BJ: Prevalence of human T-cell leukemia/lymphoma virus (HTLV) type II infection among high-risk individuals: Type-specific identification of HTLVs by polymerase chain reaction. Blood 1989;74(5):1658- 1664. (Pubitemid 19251543)
56. Lee H, Swanson P, and Shorty VS: High rate of HTLV-II infection in seropositive IV drug abusers in New Orleans. Science 1989;244(4903):471-475. (Pubitemid 19127507)
57. Wattel E, Mariotti M, Agis F, Gordien E, Prou O, Courouce AM, Rouger P, Wain-Hobson S, Chen IS, and Lefrere JJ: Human T lymphotropic virus (HTLV) type I and II DNA amplification in HTLV-I/II-seropositive blood donors of the French West Indies. J Infect Dis 1992;165(2):369-372.
58. Wiktor SZ, Alexander SS, Shaw GM, Weiss SH, Murphy EL, Wilks RJ, Shortly VJ, Hanchard B, and Blattner WA: Distinguishing between HTLV-I and HTLV-II by Western blot [letter]. Lancet 1990;335(8704):1533. (Pubitemid 20224952)
59. Chavance M, Neisson-Vernant C, Quist D, Monplaisir N, Armengaud B, and Chout R: HIV/HTLV-I coinfection and clinical grade at diagnosis. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8(1):91-95.
60. Gotuzzo E, Escamilla J, Phillips IA, Sanchez J, Wignall FS, and Antigoni J: The impact of human T-lymphotrophic virus type I/II infection on the prognosis of sexually acquired cases of acquired immunodeficiency syndrome. Arch Intern Med 1992;152(7):1429-1373.
61. Cleghorn FR and Blattner WA: Does human T-cell lymphotropic virus type I and human immunodeficiency virus type 1 coinfection accelerate acquired immunodeficiency syndrome? The jury is still out (editorial). Arch Intern Med 1992;152(7):1372-1373.
62. Volberding PA: HIV, HTLV-I, and CD4+ lymphocytes: Troubles in the relationship (editorial). JAMA 1994;271(5):392-393.
63. Hershow RC, Galai N, Fukuda K, Graber J, Vlahov D, Rezza G, Klein RS, Des Jarlais DC, Vitek C, Khabbaz R, Freels S, Zuckerman R, Pezzotti P, and Kaplan JE: An international collaborative study of the effects of coinfection with human T-lymphotropic virus type II on human immunodeficiency virus type 1 disease progression in injection drug users. J Infect Dis 1996;174(2):309-317. (Pubitemid 26251416)
64. Schechter M, Moulton LH, and Harrison LH: HIV Viral load and CD4 + lymphocyte counts in subjects coinfected with HTLV-I and HIV-1. J Acquir Immune Defic Syndr Hum Retrovirol 1997;15(4):308-311. (Pubitemid 27432729)
65. Hill SA, Lloyd PA, McDonald S, Wykoff J, and Derse D: Susceptibility of human T cell leukemia virus type I to nucleoside reverse transcriptase inhibitors. J Infect Dis 2003; 188(2):424-427. (Pubitemid 36960653)
66. Powderly WG: Significance of HIV/HTLV coinfection? Editorial. In http://www.medscape.com/viewarticle/440640. 2002.
67. Turci M, Pilotti E, Ronzi P, Magnani G, Boschini A, Parisi SG, Zipeto D, Lisa A, Casoli C, and Bertazzoni U: Coinfection with HIV-1 and human T-cell lymphotropic virus type II in intravenous drug users is associated with delayed progression to AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 2006;41(1):100-106. (Pubitemid 41786027)
68. Bassini S, Lopez M, Toro C, Jiménez V, Sempere JM, Soriano V, and Benito JM: Influence of human T cell lymphotropic virus type 2 coinfection on virological and immunological parameters in HIV type 1-infected patients. Clin Infect Dis 2007;44(1):105-110. (Pubitemid 44968994)
69. Brites C, Sampaio J, and Oliveira A: HIV/Human T-cell lymphotropic virus coinfection revisited: Impact on AIDS progression. AIDS Rev 2009;11(1):8-16.
70. Brites C, Alencar R, Gusmão R, Pedroso C, Netto EM, Pedral- Sampalo D, and Bardaró R: Co-infection with HTLV-1 is associated with a shorter survival time for HIV-1-infected patients in Bahia, Brazil. AIDS 2001;15(15):2053-2055. (Pubitemid 32982162)
71. Pedroso C, Netto EM, Weyll N, and Brites C: Coinfection by HIV-1 and human lymphotropic virus type 1 in Brazilian children is strongly associated with a shorter survival time. J Acquir Immune Defic Syndr Hum Retrovirol 2011;57(Suppl 3):S208-S211.
72. Beilke MA, Theall KP, O'Brien M, Clayton JL, Benjamin SM, Winsor EL, and Kissinger PJ: Clinical outcomes and disease progression among patients coinfected with HIV and human T lymphotropic virus types 1 and 2. Clin Infec Dis 2004;39(2):256-263. (Pubitemid 38971498)
73. Beilke MA, Japa S, Moeller-Hadi C, and Martin-Schild S: Tropical spastic paraparesis/human T leukemia virus type 1-associated myelopathy in HIV type 1-coinfected patients. Clin Infect Dis 2005;41(6):e57-e63.
74. Beilke MA, Traina-Dorge VL, Sirois M, Bhuiyan A, Murphy EL, Walls JM, Fagan R, Winsor EL, and Kissinger PJ: Relationship between human T lymphotropic virus (HTLV) type 1/2 viral burden and clinical and treatment parameters among patients with HIV type 1 and HTLV-1/2 coinfection. Clin Infect Dis 2007;44(9):1229-1234. (Pubitemid 46651250)
75. Casseb J, Posada-Vergara MP, Montanheira P, Fukumori LMI, Olah I, Smid J, Duarto AJ, and Penaiva de Oliveira AC: T CD4+ cell counts among patients co-infected with human immunodeficiency virus type 1 (HIV-1) and human T-cell leukemia virus type 1 (HTLV-1): High prevalence of tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/ HAM). Revist Instit Med Trop Sao Paulo 2007;49(4):231-233. (Pubitemid 47403207)
76. Casoli C, Pilotti E, and Bertazzoni U: Molecular and cellular interactions of HIV-1/HTLV coinfection and impact on AIDS progression. AIDS Rev 2007;9(3):140-149. (Pubitemid 350001485)
77. Beilke MA, Japa S, and Vinson DG: HTLV-I and HTLV-II virus expression increase with HIV-1 coinfection. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17(5):391-397.
78. Murphy EL, Grant RM, Kropp J, Oliviera A, Lee T-H, and Busch MP: Increased human T-lymphotropic virus type II proviral load following highly active retroviral therapy in HIV-coinfected patients. J Acquir Immune Defic Syndr Hum Retrovirol 2003;33(5):655-656. (Pubitemid 36975858)
79. Cesaire R, Dehee A, Lezin A, Desire N, Bourdonne O, Dantin F, Bera O, Smadja D, Abel S, Cabie A, Sobesky G, and Nicolas JC: Quantification of HTLV type I and HIV type 1 DNA load in coinfected patients: HIV type 1 infection does not alter HTLV type I proviral amount in the peripheral blood compartment. AIDS Res Hum Retrovirus 2001;17(9):799-805. (Pubitemid 32692395)
80. Boxus M, Twizere JC, Legros S, Dewulf JF, Kettmann R, and Willems L: The HTLV-1 Tax interactome. Retrovirology 2008;5(76):1-24.
81. Banerjee P, Rochford R, Antel J, Canute G, Wrzesinski S, Sieburg M, and Feuer G: Proinflammatory cytokine gene induction by human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2 Tax in primary human glial cells. J Virol 2007;81(4):1690-1700. (Pubitemid 46214444)
82. Yamano Y, Nagai M, Brennan M, Mora CA, Soldan SS, Tomaru U, Takenouchi N, Izumo S, Osame M, and Jacobson S: Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virus-specific CD8(+) T cells, and disease severity in HTLV-1-associated myelopathy (HAM/TSP). Blood 2002;99(1):88-94.
83. Higuchi M and Fujii M: Distinct functions of HTLV-1 Tax1 from HTLV-2 Tax2 contribute key roles to viral pathogenesis. Retrovirology 2009;6(117):1-11.
84. Bertazzoni U, Turci M, Avesani F, DiiGennaro G, Bidoia C, and Romanelli MG: Intracellular localization and cellular factors interaction of HTLV-1 and HTLV-2 Tax proteins: Similarities and functional differences. Viruses 2011;3(5):541-560.
85. Lewis MJ, Gautier VW, Wang XP, Kaplan MH, and Hall WW: Spontaneous production of C-C chemokines by individuals infected with human T lymphotropic virus type II (HTLV-II) alone and HTLV-II/HIV-1 coinfected individuals. J Immunol 2000;165(7):4127-4132. (Pubitemid 32057325)
86. Casoli C, Vicenzi E, Cimarelli A, Magnani G, Ciancianaini P, Cattaneo E, Dall'Algio PP, Poli G, and Bertazzoni U: HTLV-II down-regulates HIV-1 replication in IL-2-stimulated primary PBMC of coinfected individuals through expression of MIP-1a. Blood 2000;95(9):2760-2769. (Pubitemid 30235881)
87. Pilotti E, Elviri L, Vicenzi E, Bertazzoni Um Re MC, Allibardi S, Poli G, and Casoli C: Postgenomic up-regulation of CCL3L1 expression in HTLV-2-infected persons curtails HIV-1 replication. Blood 2007;109(5):1850-1856. (Pubitemid 46348179)
88. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, and Paxton WA: HIV-1 entry into CD4+ cells is mediated by the chemokines receptor CC-CKR-5. Nature 1996;381(6584):667-673. (Pubitemid 26197680)
89. Bates P: Chemokine receptors and HIV-1: An attractive pair? Cell 1996;86(1):1-3.
90. Paxton WA, Martin SR, Tse D, O'Brien TR, Skurnick J, VanDevanter NL, Padian N, Braun JF, Kotler DP, Wolinsky SM, and Koup RA: Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposures. Nat Med 1996;2(4):412-417. (Pubitemid 26191912)
91. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, and Lusso P: Identification of RANTES, MIP-1α, and MIP-1β as the major HIV-suppressive factor produced by CD8+ T cells. Science 1995;270(5243):1811- 1815.
92. Garzino-Demo A, Moss RB, Margolick JB, Cleghorn F, Sill A, Blattner WA, Cocchi F, Carlo DJ, DeVico AL, and Gallo RC: Spontaneous and antigen-induced production of HIV-inhibitory beta-chemokines are associated with AIDS-free status. Proc Natl Acad Sci USA 1999;96(21):11986-11991. (Pubitemid 29502845)
93. Cocchi F, DeVico AL, Yarchoan R, Redfield R, Cleghorn F, Blattner WA, Garzino-Demo A, Colombini-Hatch S, Margolis D, and Gallo RC: Higher macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels from CD8 + T cells are associated with asymptomatic HIV-1 infection. Proc Natl Acad Sci USA 2000;97(25):13812-13817.
94. Barrios CS, Abuerreish M, Lairmore MD, Wu L, Castillo L, Giam C-Z, and Beilke MA: Recombinant human T-cell leukemia virus types 1 and 2 Tax proteins induce high levels of CCchemokines and downregulate CCR5 in human peripheral blood mononuclear cells. Viral Immunol 2011;24(6):1-11.
95. Matsuoka M and Green PL: The HBZ gene, a key player in HTLV-1 pathogenesis. Retrovirology 2009;6:71.
96. Halin M, Douceron E, Clerc I, Journo C, Ko NL, Landry S, Murphy EL, Gessain A, Lemasson I, Mesnard J-M, Barbeau B, and Mahieux R: Human T-cell leukemia virus type 2 produces a spliced antisense transcript encoding a protein that lacks a classic bZIP domain but still inhibits Tax2-mediated transcription. Blood 2009;114(12):2724-2438.